Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04198766 · ClinicalTrials.gov registry record · Phase 1
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
A Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Inhibrx Biosciences.
- Active
- Registry status
- Phase 1
- Development phase
- 296
- Enrollment target
- 20
- Study locations
NCT04198766: Active Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Inhibrx Biosciences.
NCT04198766 is a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma that is active but no longer recruiting, run by Inhibrx Biosciences. The registered enrollment target is 296 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04198766, a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, is active but no longer recruiting, sponsored by Inhibrx Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 296 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.
Primary Outcome
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0
Conditions Studied
Interventions
- DRUG INBRX-106 - Hexavalent OX40 agonist antibody
- DRUG pembrolizumab 200 mg
- DRUG pembrolizumab 400 mg
- DRUG Carboplatin AUC-5
- DRUG Carboplatin AUC-6
Study Locations (20)
California
- City of Hope - Duarte
- Los Angeles Cancer Network - Glendale
- California Research Institute - Los Angeles
- Valkyrie Clinical Trials - Los Angeles
- Valkyrie Clinical Trials - Murrieta
- Providence Medical Foundation - Santa Rosa
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
- Henry Ford Cancer Institute - Detroit
- START Midwest - Grand Rapids
Florida
- Clermont Oncology Center - Clermont
- Mid Florida Hematology and Oncology Center - Orange City
Minnesota
- HealthPartners Cancer Research Center - Saint Louis Park
- HealthPartners Cancer Research Center (Regions Hospital) - Saint Paul
Georgia
- Winship Cancer Institute - Emory University - Atlanta
Illinois
- The University of Chicago Medical Center - Chicago
Iowa
- University of Iowa - Iowa City
Kentucky
- Norton Cancer Institute - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 296 participants |
| Start Date | 2019-12-10 |
| Est. Completion | 2027-05-12 |
| Phase | Phase 1 |
What the registry record for NCT04198766 still lists
NCT04198766 is an interventional study that assigns participants to a tested intervention. The registered 296 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (55% lower).
The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which INBRX-106 - Hexavalent OX40 agonist antibody is the first listed.
NCT04198766 names 20 study sites across 11 states, led by California, Michigan, Florida.
Frequently Asked Questions
What is clinical trial NCT04198766 about?
NCT04198766 is a clinical study titled "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)". This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab...
What is the current status of trial NCT04198766?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 296 participants. The study started on 2019-12-10. Estimated completion is 2027-05-12.
What conditions does trial NCT04198766 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Head and Neck Cancer, Solid Tumor, Gastric Cancer.
What interventions are being tested in trial NCT04198766?
The interventions under investigation include: INBRX-106 - Hexavalent OX40 agonist antibody (DRUG), pembrolizumab 200 mg (DRUG), pembrolizumab 400 mg (DRUG), Carboplatin AUC-5 (DRUG), Carboplatin AUC-6 (DRUG).
Who is sponsoring clinical trial NCT04198766?
This trial is sponsored by Inhibrx Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04198766 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04198766's enrollment target sits among peer trials
296 127th of 454 higher than 328 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05563792 · 296 participants · NA
Options for Pain Management Using Nonpharmacological Strategies
- NCT06828445 · 296 participants · Phase 1
Increasing Affordable Fruits and Vegetables for Families With Food Insecurity
- NCT06920563 · 296 participants · NA
Remote Postpartum Blood Pressure Monitoring and Cardiovascular Education
- NCT06309160 · 297 participants · NA
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI